2012-11-27 08:17:30 -
MorphoSys AG /
MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys to Participate in Lanthio Pharma's Series A Financing
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced a
collaboration with privately held Lanthio Pharma, a Dutch biopharmaceutical
company focused on discovering and developing lantipeptides. Lantipeptides
comprise a novel class of therapeutics with high target selectivity and improved
drug-like properties. Lanthio Pharma's technology LanthioPep can be used to
identify peptides which are selective
for a specific disease target and to
stabilize them in their optimal structural conformation for receptor binding.
MorphoSys and Lanthio Pharma will jointly apply their respective technologies to
establish high quality and diverse lantipeptide-based libraries. MorphoSys
receives preferred rights to exclusively license the LanthioPep technology for
MorphoSys will also make an equity investment in Lanthio Pharma as part of the
company's Series A financing round. After closure of the transaction, MorphoSys
will have a minority stake in Lanthio Pharma.
"Therapeutic peptides and especially so called stapled or constrained peptides
comprise an emerging compound class which offers the potential to address
multiple target classes and disease categories currently beyond reach for
therapeutic proteins or small molecules. The combination of Lanthio Pharma's
platform and our expertise in intelligent library design offers unique
opportunities for both companies and that's what got us excited," commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"We are very pleased to have access to this novel technology platform and
promising class of therapeutic peptides," commented Jens Holstein, Chief
Financial Officer of MorphoSys. "This transaction represents a new approach for
MorphoSys providing innovation capital to promising start-ups with technologies
and product candidates being close to our core capabilities."
Lanthio Pharma applies its proprietary LanthioPep technology to discover peptide
therapeutics with increased resistance to peptidase degradation, high receptor
specificity and increased intrinsic activity. The high specificity can open up
new therapeutic applications around novel targets including intracellular
targets and GPCRs. Therapeutic plasma levels of lantipeptides can potentially be
achieved via oral, pulmonary or subcutaneous delivery. The technology includes a
proprietary bacterial display capability, which allows for the construction of
focused or diversified libraries of lanthionine-peptides. These libraries allow
for immediate functional screening and easy production of peptides of interest
for further in vivo and in vitro testing. Lanthio Pharma signed a partnering
deal for its lead compound PanCyte, a lanthionine-stabilized Angiotensin-(1-7)
agonistic peptide for the treatment of pulmonary indications, with US-based
Tarix Pharmaceuticals, Inc. in 2012. The start of clinical development of
PanCyte is expected in 2013.
"Peptides are an attractive class of drugs, because they are used by the body
itself to regulate physiological processes. A drawback of using peptides
therapeutically can be their ability to interact with several receptors and
their rapid degradation by peptidases in the body. Lanthio Pharma's technology
can make peptides more receptor specific and the introduction of lanthionines
also provides strong protection against peptidase degradation. As such, our
lantipeptides typically have better "drug-like" properties, compared to natural
linear peptides. In combination with MorphoSys's outstanding capabilities in
generating high-quality protein libraries we are confident that we can bring
lantipeptides to the next level," commented Bart Wuurman, CEO of Lanthio Pharma.
About Lanthio Pharma:
Lanthio Pharma is a privately held drug discovery company that applies its
proprietary Lactococcus lactis based lanthionine-peptide drug discovery
(LanthioPep) technology to discover peptide therapeutics with increased
resistance to peptidase degradation, high receptor specificity and increased
Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides
with highly specific agonistic activity for a number of GPCR targets, which is a
focus area of the company. Many peptide ligands are thought to bind to their
GPCR receptors via a "turn motif", which can be stabilized in Lanthio Pharma's
peptides with a strong thioether bond. Fixing the turn motif in its optimal
receptor binding conformation can result in potent and specific agonistic
The technology also includes a proprietary bacterial display library capability,
which allows for the construction of focused or randomized libraries. These
libraries allow for immediate functional screening and easy production of
peptides of interest for further in-vivo and in-vitro testing.
Therapeutic products in Lanthio Pharma's pipeline include a lanthionine-
stabilized specific agonist of the AT2 receptor, which has great potential in
diseases where tissue protection is important, like fibrosis.
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®)
and Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE